A Precision Therapeutics Company

About Precidiag

Precidiag, Inc. employs a proprietary discovery platform to develop targeted therapeutics and companion diagnostics for a variety of diseases and disorders. Precidiag’s approach utilizes genomic and functional readouts of the human gut microbiota, machine learning, and artificial intelligence to determine and exploit the gut microbiome’s role in the cause and/or progression of certain diseases. The Company, based in Watertown, Massachusetts, has raised $8 million to date.

120221 New Website Image.jpeg
WeChat Image_20200715105756.jpg
A Paradigm Shift

At Precidiag, we believe we are in the midst of a revolution in the way medicine will be developed and administered. Drug development of the past was working from incomplete knowledge of the complexity of the diseases they were striving to alleviate. Little was known regarding the contribution of the over 100 trillion microorganisms within the human gut microbiota, which we now know play a central role in our health and development. The complexity of these communities is enormous, but advancements in machine learning provide the tools to decode this important component of our health. With estimates that the microbiota has a role in the etiology and/or pathogenesis of up to 90% of chronic diseases, we believe we are helping shape the future of medicine.

Precidiag's Current Pipeline

The Company’s focus is currently in the two following programs:

Inflammatory Bowel Disease – Ulcerative Colitis

  • Precidiag’s lead program is developing targeted therapeutics for Ulcerative Colitis (UC). Globally, more than 5 million people suffer from UC with incidence rates continuing to grow.

  • Precidiag has identified a potential causative role for a commensal bacterium that populates the gut. We have further identified specific protein targets of this bacterium that could be damaging the epithelial barrier of the gut.

  • Precidiag’s approach could change the paradigm of care from the emphasis on symptom management to a focus on treating the cause of the disease.

  • The Company’s research suggests that the therapeutic could provide relief for >30% of individuals with Ulcerative Colitis.

Unmet need: There is currently no cure for Ulcerative Colitis.

Opportunity:  UC drug market is forecasted to grow from USD 6.0 billion to USD 8.0 billion – USD 9.7 billion by 2026 (CAGR of ~ 6.5%).

Timing: Target IND Application in 2025.

Autism Spectrum Disorder (ASD)


  • ASD is a neurological disorder that impacts more than 70 million people worldwide and 1 in 54 individuals in the US. Approximately 85% of diagnosed ASD cases are unexplained or idiopathic.

  • Research has shown that the gut microbiome is altered in people with ASD and that fecal transplantation may improve patient symptoms.

  • Precidiag’s initial product will be a diagnostic aid to determine the likelihood of a diagnosis of ASD.

  • Precidiag is further leveraging its platform to identify targeted therapeutics for the core symptoms of ASD.

  • In September 2021, Precidiag launched one of the largest studies to date investigating the human gut microbiota and ASD. Our study is in collaboration with Massachusetts General Hospital and the Lurie Center for Autism.

Unmet need: There are no approved medications specifically developed for ASD and limited diagnostic aids. 

Opportunity: 70 million+ Global Market. Projected USD 0.5 billion in revenues by 2028.

Timing: ASD screening test projected launch in 2024/2025.